Frequency of ADAs, detection of NAbs, and relative expression of CD123 on blasts. (A) Median anti-TAG and anti–IL-3 ADA titers during 5 cycles of tagraxofusp treatment, N = 30. (B) Presence or absence of anti-TAG NAb (n = 10) and anti–IL-3 NAb (n = 29) over 11 cycles of tagraxofusp treatment. (C) The relative expression of CD123 on blasts in the peripheral blood (PB) and BMA, n = 7 with a range of posttreatment samples from 3 to 10. TAG, tagraxofusp.
Figure 4.

Frequency of ADAs, detection of NAbs, and relative expression of CD123 on blasts. (A) Median anti-TAG and anti–IL-3 ADA titers during 5 cycles of tagraxofusp treatment, N = 30. (B) Presence or absence of anti-TAG NAb (n = 10) and anti–IL-3 NAb (n = 29) over 11 cycles of tagraxofusp treatment. (C) The relative expression of CD123 on blasts in the peripheral blood (PB) and BMA, n = 7 with a range of posttreatment samples from 3 to 10. TAG, tagraxofusp.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal